Gymnema (Gurmar) Delivery Formats: Capsule, Gummy, or Lozenge
Buyer’s snapshot
- Gymnemic acids work by binding the human sweet-taste receptor. A 2014 study in the Journal of Biological Chemistry placed the effect on the transmembrane domain of human T1R3, at the same site the sweetness inhibitor lactisole binds, and found no effect at all on the mouse receptor.
- That one mechanism splits the category in two. A swallowed capsule or tablet carries the systemic glycaemic-support platform and bypasses the tongue entirely. A mint, lozenge, or chewable carries the craving-suppression platform, which only works on oral contact.
- Gummies sit in the worst position of the four formats. The dominant US patent in the craving-suppression space states plainly that sweetener-based taste masking fails on gymnemic acid, because sweeteners and gymnemic acid compete for the same receptor. FDA rules then push the resulting sugar load onto the Supplement Facts panel as declared added sugars.
- Format economics pull the other way. Informa’s 2025 Supplement Business Report, reported by NutraIngredients in January 2026, puts gummies at roughly a quarter of the US supplement market against roughly a third for pill formats, inside a market Nutrition Business Journal sized at USD 74.15 billion for 2025.
- Silk Foods Ceylon mills gurmar leaf powder in Matale on a BRCGS and FSSC 22000 V6 audited line at 100 to 200 kg per hour and encapsulates at 100,000 capsules per shift, with a 50 kg minimum per SKU on bulk and 180 bottles on capsules. For a gummy or a compressed chewable, the Matale site supplies the raw material rather than the finished format.
Most gurmar briefs that reach a Sri Lankan exporter arrive with the format already fixed and the claim still undecided. The brief asks for gymnema at 75% gymnemic acids, in a gummy, for a blood-sugar-support SKU, because gummies are what the buyer’s category is doing. Then the first pilot batch comes back bitter, the sweetener load climbs to cover it, and the finished gummy still tastes wrong.
That is not a manufacturing failure. It is a chemistry constraint that was decided before anyone chose a format. Gymnema sylvestre is one of the few botanicals whose primary mechanism is an interaction with the tongue, which means the delivery format is not a packaging decision for this ingredient. It is a claim decision. This piece separates the two claim platforms, gives the format matrix that follows from each, and sets out what to write into the sourcing brief. For the underlying raw-material specification, grades, and contaminant panel, the companion piece on sourcing gymnema sylvestre (gurmar) for blood-sugar SKUs is the reference document.
What does gymnemic acid actually do at the sweet receptor?
It occupies the receptor the sweetener needs. Sanematsu and colleagues, publishing in the Journal of Biological Chemistry in 2014, expressed the human sweet receptor pair T1R2 and T1R3 in HEK293 cells and showed that gymnemic acids at 100 micrograms per millilitre suppressed the calcium response to sweet compounds. The same treatment did nothing to the mouse receptor. Modelling put the binding pocket on the transmembrane domain of human T1R3, overlapping the site used by lactisole, and only gamma-cyclodextrin restored the sweet response afterwards.
Two consequences follow directly, and both are commercial rather than academic. First, the effect is topical in the literal sense: it happens where the material touches the tongue. Swallow it inside a capsule shell and the sweetness-suppression effect is discarded by design. Second, sweeteners cannot be used to mask the taste of the material, because a sweetener is precisely the class of molecule the ingredient is blocking. The taste problem and the mechanism are the same problem.
How long the block lasts is the one number the sources do not agree on. The 2025 randomised crossover trial in Appetite worked to a window in the region of 30 to 60 minutes, while the patent literature claims 60 to 80 minutes or longer at higher loadings. A brand writing dosing instructions should treat 30 to 60 minutes as the defensible published range and validate its own material rather than lifting a single figure from a supplier’s sales sheet.
Two claim platforms, not one ingredient
The gurmar category behaves as though it sells one benefit. It sells two, and they have opposite format requirements.
The glycaemic-support platform is the traditional one: gurmar taken daily as part of a blood-sugar-support stack, usually alongside cinnamon, chromium, or berberine. It is systemic, it does not require oral contact, and taste is a nuisance rather than a design input. Capsules and tablets serve it.
The craving-suppression platform is newer in Western retail and much more specific. The 2025 trial in Appetite ran 32 adults who described themselves as high consumers of sweet foods through a randomised crossover, using a mint delivering 4 mg of Gymnema sylvestre standardised to 75% gymnemic acids. Taken ad libitum, the regimen cut sugar-sweetened beverage intake by 42% against placebo (p = 0.015) and reduced overall sugar cravings by 28% (p = 0.045). The dose is small. The format is the active part of the design.
Read that trial as a formulator and the instruction is unusually clear. The clinically studied craving product is a low-dose oral-contact format, not a 500 mg capsule and not a gummy. A brand that copies the claim while changing the format has changed the intervention.
Capsule, tablet, gummy, or lozenge: matching format to claim
| Format | Claim platform it serves | Typical gurmar load | Where it breaks |
|---|---|---|---|
| Two-piece capsule | Glycaemic support, daily stack | 300 to 500 mg leaf powder or extract per capsule | Discards the oral-contact effect entirely; no craving claim is defensible from this format |
| Compressed tablet | Glycaemic support; craving support only if uncoated and chewed | 300 to 600 mg with binders and flow agents | A coated swallow tablet behaves like a capsule; an uncoated chewable inherits the full bitterness problem |
| Unsweetened mint or lozenge | Craving suppression, dosed before a sweet exposure | 4 mg standardised extract in the published trial design | Bitterness is managed by cooling and aromatic notes, not by sweetness; consumer acceptance is the commercial risk |
| Gummy | Neither platform cleanly | Limited by the confectionery matrix | Sweetener masking is blocked by the mechanism itself; added sugars land on the Supplement Facts panel; water activity shortens shelf life |
| Powder stick pack | Glycaemic support if mixed into an unsweetened base | 500 mg to 2 g depending on the blend | Any sweetened beverage base puts the ingredient and the flavour system in direct conflict |
The pattern in the right-hand column is worth stating plainly. Three of the five formats are viable for one platform each. One format, the gummy, is viable for neither, and it is the format the category is growing fastest into.
Why gummies are the hardest format for this botanical
Start with the party that has the strongest commercial incentive to solve the problem. US patent 9,585,905 B2, covering sweet-taste-receptor antagonist compositions, describes gymnemic acid as having an intense bitter taste that is unpalatable to humans, then rules out the two obvious fixes in the same document. Sweetener-based masking fails because sweeteners and gymnemic acid bind at the same receptor. Encapsulation fails because the dosage form has to contact the oral cavity to work at all. When the applicant with the most to gain from a workaround publishes the constraint as prior art, the constraint is real.
Labelling adds the second cost. Added sugars are a declared dietary ingredient on the Supplement Facts panel under 21 CFR 101.36, so the sugar a gummy needs for structure and palatability appears on the panel the buyer is trying to keep clean. Sugar alcohols shift the problem rather than removing it, and they carry their own tolerance thresholds.
Stability is the third. A 2024 study in Polymers on gummies fortified with a botanical extract measured water activity between 0.717 and 0.792 at production and moisture around 25 to 30%, against the 10 to 20% typical of standard gummy candy, at a pH between 3.54 and 3.91. Roughly 90% of the marker compounds survived production, but the authors recommended a storage window of only about 45 days. That study used mountain germander rather than gymnema, so read it as an indication of how botanicals behave inside a gelled sugar matrix rather than as gurmar-specific data. The direction of travel is the useful part: a wet, acidic, sugar-heavy matrix is a demanding environment for a saponin fraction that the buyer is paying an assay premium for.
On a Thursday in March 2025, NutraIngredients ran the Appetite trial under a headline calling gurmar the sugar destroyer, and the category read it as a green light. What the study actually validated was a 4 mg mint. The distance between those two readings is where most of this year’s failed gummy pilots live.
What “75% gymnemic acids” does and does not tell you
Less than the number implies. The EFSA 2018 assessment of Gymnema sylvestre concluded that the available information was not sufficient to derive health-based guidance values, and noted specifically that preparations are standardised against varying percentages of gymnemic acid, which is itself a mixture of different compounds. A 2014 review in Natural Product Communications went further, describing gymnemic acid as a complex mixture of dozens of substances that carries a CAS number without a specified structure.
So a 75% figure is a gravimetric fraction of a defined analytical method, not a purity statement about a single molecule. Change the method and the number moves. A 2025 paper in the Journal of Liquid Chromatography and Related Technologies found methanol extraction returned the highest total gymnemic acids at 4.69% weight for weight against ethanol and aqueous routes, and confirmed three major saponins by LC-MS/MS, including deacyl gymnemic acid and gymnemic acid IV.
The procurement consequence is direct. Two suppliers quoting 75% gymnemic acids are not necessarily quoting the same material, and neither number is comparable unless the method behind it is stated. Ask for the marker-level chromatography, not the headline percentage.
Spec snapshot: gurmar for finished-format manufacture
Botanical identity: Gymnema sylvestre, leaf, confirmed against a retained reference sample
Standardisation: state the analytical method alongside the percentage, and require the same method batch to batch
Marker data: LC-MS/MS or HPLC profile naming the saponins quantified, not a single gravimetric figure
Particle size: 80 or 100 mesh for encapsulation; tighter distribution for direct compression
Contaminants: heavy metals, microbiology, and a pesticide-residue panel aligned to the destination market
Certification: BRCGS and FSSC 22000 V6 on the processing line; USDA Organic and EU Organic held per SKU
Minimum: 50 kg per SKU on bulk raw material; 180 bottles on encapsulated finished goods
There is one further point that belongs in a safety brief rather than a spec sheet. EFSA’s assessment recorded that in one 1990 clinical study, 23% of patients discontinued conventional antidiabetic therapy after supplementing with gymnema, and warned that combined use without medical supervision may carry risk. That is a labelling and claim-boundary matter for the brand owner, and it is a reason to keep the claim language conservative regardless of format.
Specifying the format in a sourcing brief
Most gurmar briefs specify the material and leave the format to the co-packer. Reverse the order. The format determines which specification is even relevant.
| Decision | What to write into the brief | Why it is there |
|---|---|---|
| Claim platform | State glycaemic support or craving suppression, not both | The two platforms require opposite formats; a brief that hedges gets the wrong sample |
| Format | Name the format and whether the dose contacts the tongue | Oral contact is the switch that turns the sweetness-suppression mechanism on or off |
| Dose per unit | State milligrams of material and the standardisation basis separately | 4 mg at 75% and 400 mg of leaf powder are different products with different price structures |
| Assay method | Name the method used to generate the percentage | Gymnemic acid is a mixture; the percentage is method-dependent |
| Flavour system | For oral-contact formats, specify cooling and aromatic masking, not sweeteners | Sweeteners compete with the active at the same receptor |
| Sugar declaration | For any sweetened format, model the added-sugars line before formulating | 21 CFR 101.36 puts it on the Supplement Facts panel |
| Shelf life | For gelled or high-moisture formats, require stability data on the marker compounds alongside microbiology | Marker loss in a wet acidic matrix is the risk the COA does not cover |
| Volume tier | State first-order and 12-month projected volume per SKU | Determines whether a dedicated format run is economic at all |
Where Silk Route Ventures walks away
Gummy and compressed-chewable finished goods. The Matale site runs powder, encapsulation, spreads, beverages, plant-based, and spray-dried lines, and does not run a confectionery gelling line. A buyer who wants a gurmar gummy should source the leaf powder or extract from SRV against the spec above and place the gelling run with a confectionery co-packer. Recommending a format the site cannot make well is not a service.
How does Silk Foods Ceylon manufacture gurmar formats?
Two of them, in Matale. The herb milling line runs at 100 to 200 kg per hour and produces gurmar leaf powder at 80 or 100 mesh against the buyer’s particle-size and contaminant specification, with a COA on every batch and traceability held to farm level for the organic SKUs. The encapsulation line runs 100,000 capsules per single shift and 200,000 per day, with a minimum of 180 bottles for a private-label run, which is the same threshold set out in the piece on capsule contract manufacturing MOQ.
Samples ship door to door by international courier at 3 to 5 business days. Production lead time from PO to dispatch is 2 to 3 weeks, with sea freight adding 4 to 5 weeks to the US and 3 to 4 weeks to the EU. Buyers building a multi-botanical blood-sugar stack usually specify gurmar alongside cinnamon, and the cinnamon capsule spec for blood-sugar-claim SKUs covers the species-identity discipline that pairing needs.
Frequently asked questions
Can gymnema be formulated into a gummy?
Technically yes, commercially rarely. US patent 9,585,905 B2 records that sweetener-based masking fails on gymnemic acid because sweeteners bind the same receptor the ingredient blocks. Added sugars must also be declared on the Supplement Facts panel under 21 CFR 101.36, and gelled matrices carry high water activity that shortens the stability window for saponin markers.
Does a gurmar capsule still suppress sweet cravings?
No. The 2014 Journal of Biological Chemistry work located the effect on the transmembrane domain of the human T1R3 receptor, which the material has to reach by direct oral contact. A capsule swallowed whole bypasses the tongue, so it can support a systemic glycaemic-support position but not a taste-mediated craving claim.
What dose was used in the 2025 gymnema craving trial?
The randomised crossover published in Appetite in 2025 used a mint delivering 4 mg of Gymnema sylvestre standardised to 75% gymnemic acids across 32 adults. Ad libitum use reduced sugar-sweetened beverage intake by 42% against placebo and overall sugar cravings by 28%.
Is 75% gymnemic acids a meaningful specification?
Only with the method attached. EFSA noted in 2018 that gymnemic acid is itself a mixture standardised at varying percentages, and a 2014 review described it as carrying a CAS number without a specified structure. Require the analytical method and marker-level chromatography alongside the percentage figure.
What is the contract manufacturing MOQ for gurmar capsules at Silk Foods Ceylon?
The encapsulation line in Matale runs 100,000 capsules per single shift with a private-label minimum of 180 bottles, and bulk gurmar leaf powder carries a 50 kg minimum per SKU. Samples ship by international courier at 3 to 5 business days, with production lead time of 2 to 3 weeks from PO.
How Silk Route Ventures can help
Silk Route Ventures (SRV) supplies gurmar leaf powder and manufactures finished capsule SKUs for wellness and nutraceutical brands from the Silk Foods Ceylon (SFC) facility in Matale, milled at 100 to 200 kg per hour and encapsulated at 100,000 capsules per single shift. The site holds BRCGS on the relevant lines and FSSC 22000 V6 across the full processing scope, with USDA Organic and EU Organic held per SKU and a COA on every batch. Because the format decision on this ingredient sets the claim boundary rather than following it, the SRV team scopes claim platform, standardisation method, and format economics together before quoting. The minimum is 50 kg per SKU on bulk and 180 bottles on capsules. Contact us to request a sample against your specification, or a capability briefing for your target format and launch volume. For adjacent botanicals in the same stack, the garcinia capsule formulation guide and the overview of herbal supplement capsules from Sri Lanka cover the same specification discipline.
Sources
- Sanematsu K., Kusakabe Y., Shigemura N., Hirokawa T., Nakamura S., Imoto T. and Ninomiya Y., molecular mechanisms for sweet-suppressing effect of gymnemic acids, Journal of Biological Chemistry, 2014, 289(37):25711-20. https://pubmed.ncbi.nlm.nih.gov/25056955/ (retrieved 6 August 2026)
- Hsiao W.H., Kruger R., Diako C., Nelson I., Stice E. and Ali A., effect of a 14-day Gymnema sylvestre intervention on sweet taste, sugar intake and cravings, Appetite, 2025. https://pubmed.ncbi.nlm.nih.gov/39855349/ (retrieved 6 August 2026)
- European Food Safety Authority, risk assessment of Gymnema sylvestre and its preparations, EFSA Journal, 2018, 16(Suppl 1):e16083. https://pmc.ncbi.nlm.nih.gov/articles/PMC7015520/ (retrieved 6 August 2026)
- Porchezhian E. and Dobriyal R.M. lineage review, history of gymnemic acid, a molecule that does not exist, Natural Product Communications, 2014, 9(10). https://journals.sagepub.com/doi/pdf/10.1177/1934578X1400901007 (retrieved 6 August 2026)
- Somasekhar V., Pai R., Prakash N.S. and Reddy M.D., analytical profiling of Gymnema sylvestre saponins by LC-MS/MS, Journal of Liquid Chromatography and Related Technologies, 2025, 48(16-20):558-564. https://www.tandfonline.com/doi/full/10.1080/10826076.2025.2528203 (retrieved 6 August 2026)
- United States Patent and Trademark Office, US 9,585,905 B2, sweet taste receptor antagonist compositions, granted 7 March 2017. https://patents.google.com/patent/US9585905B2/en (retrieved 6 August 2026)
- US Food and Drug Administration, 21 CFR 101.36, nutrition labeling of dietary supplements, eCFR current text. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-101/subpart-C/section-101.36 (retrieved 6 August 2026)
- NutraIngredients, supplement delivery formats, what is hot and what is not, reporting the Informa 2025 Supplement Business Report and SPINS data, 15 January 2026. https://www.nutraingredients.com/Article/2026/01/15/supplement-delivery-formats-whats-hot-and-whats-not/ (retrieved 6 August 2026)
- Nutrition Business Journal, 2026 Supplement Business Report, US market at USD 74.15 billion in 2025, released 2 June 2026. https://www.globenewswire.com/news-release/2026/06/02/3305453/0/en/nutrition-business-journal-releases-2026-supplement-business-report-u-s-market-surges-toward-100-billion-milestone.html (retrieved 6 August 2026)
- Polymers (Basel), physicochemical and sensory stability evaluation of gummy candies fortified with mountain germander extract and prebiotics, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC10818720/ (retrieved 6 August 2026)
- NutraIngredients, gurmar the sugar destroyer curbs sweet cravings, 13 March 2025. https://www.nutraingredients.com/Article/2025/03/13/gurmar-the-sugar-destroyer-curbs-sweet-cravings/ (retrieved 6 August 2026)
- Nelson I., Kruger R., Hsiao D., Stice E. and Ali A., Gymnema sylvestre and motivation to consume sweet foods, a qualitative study, Nutrients, 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12430398/ (retrieved 6 August 2026)
Written by the Silk Route Ventures Trade Team. Silk Route Ventures (E-Silk Route Ventures (Pvt) Ltd) is a Sri Lankan B2B supply-chain operator for the Food, Beverage, Wellness, and Nutraceuticals sectors. The Silk Foods Ceylon manufacturing arm holds BRCGS and FSSC 22000 V6 certifications. Questions or to request a sample: Contact us or email info@esilkroute.com.lk.